|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Effects of Notch signalling on the expression of SEMA3C, HMGA2, CXCL14, CXCR7, and CCL20 in breast cancer.
|
30930637 |
2019 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
BEFREE |
Our results suggest that CCL20 can be a novel predictive marker for taxane response, and the blockade of CCL20 or its downstream pathway might reverse the taxane resistance in breast cancer patients.
|
30052635 |
2018 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Our results suggest that CCL20 can be a novel predictive marker for taxane response, and the blockade of CCL20 or its downstream pathway might reverse the taxane resistance in breast cancer patients.
|
30052635 |
2018 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
BEFREE |
Moreover, CCL20 elevated the receptor activator of nuclear factors kappa-B ligand/osteoprotegerin ratio in breast cancer and osteoblastic cells and mediated the crosstalk between these cells.
|
28851919 |
2017 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Moreover, CCL20 elevated the receptor activator of nuclear factors kappa-B ligand/osteoprotegerin ratio in breast cancer and osteoblastic cells and mediated the crosstalk between these cells.
|
28851919 |
2017 |
|
Malignant neoplasm of breast
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
Rs4458204_A near CCL20 (2q36.3) is found to be associated with breast cancer-specific death at a genome-wide significant level (n=2,641, 440 events, combined allelic hazard ratio (HR)=1.81 (1.49-2.19); P for trend=1.90 × 10(-9)).
|
24937182 |
2014 |
|
Breast Carcinoma
|
0.350 |
GeneticVariation
|
disease |
BEFREE |
Rs4458204_A near CCL20 (2q36.3) is found to be associated with breast cancer-specific death at a genome-wide significant level (n=2,641, 440 events, combined allelic hazard ratio (HR)=1.81 (1.49-2.19); P for trend=1.90 × 10(-9)).
|
24937182 |
2014 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
BEFREE |
Since the microenvironment of breast cancer includes CCL20 chemokine, the purpose of this study was to determine whether CCL20 modulates the physiology of healthy breast epithelial cells in areas adjacent to the tumor.
|
23460117 |
2013 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
BEFREE |
Since the microenvironment of breast cancer includes CCL20 chemokine, the purpose of this study was to determine whether CCL20 modulates the physiology of healthy breast epithelial cells in areas adjacent to the tumor.
|
23460117 |
2013 |
|
Malignant neoplasm of breast
|
0.350 |
Biomarker
|
disease |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
|
Breast Carcinoma
|
0.350 |
Biomarker
|
disease |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
|
Malignant neoplasm of pancreas
|
0.320 |
Biomarker
|
disease |
CTD_human |
Pancreatic carcinoma cells colonizing the liver modulate the expression of their extracellular matrix genes.
|
30603057 |
2018 |
|
Malignant neoplasm of pancreas
|
0.320 |
Biomarker
|
disease |
BEFREE |
Role of CCL20 mediated immune cell recruitment in NF-κB mediated TRAIL resistance of pancreatic cancer.
|
28188806 |
2017 |
|
Malignant neoplasm of pancreas
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
CCL20/CCR6 expression profile in pancreatic cancer.
|
20459729 |
2010 |
|
Mammary Neoplasms
|
0.310 |
Biomarker
|
group |
BEFREE |
These results reveal a role for CCL20 also in tumor breast cell and point to CCL20 as a novel therapeutic target in cancer.
|
28618084 |
2017 |
|
Dermatologic disorders
|
0.310 |
Biomarker
|
group |
BEFREE |
The expression of various DC markers, MIP-3α, and E-cadherin in the tissue samples obtained from patients with warts, HPV-Bowen and HPV-unrelated skin diseases was evaluated by immunohistochemistry.
|
21715145 |
2011 |
|
Dermatologic disorders
|
0.310 |
Biomarker
|
group |
CTD_human |
Gene expression profiles in peripheral lymphocytes by arsenic exposure and skin lesion status in a Bangladeshi population.
|
16835338 |
2006 |
|
Mammary Neoplasms
|
0.310 |
Biomarker
|
group |
CTD_human |
ERE-independent ERalpha target genes differentially expressed in human breast tumors.
|
16298037 |
2005 |
|
Hepatoma, Morris
|
0.300 |
Biomarker
|
disease |
CTD_human |
Pancreatic carcinoma cells colonizing the liver modulate the expression of their extracellular matrix genes.
|
30603057 |
2018 |
|
Hepatoma, Novikoff
|
0.300 |
Biomarker
|
disease |
CTD_human |
Pancreatic carcinoma cells colonizing the liver modulate the expression of their extracellular matrix genes.
|
30603057 |
2018 |
|
Liver Neoplasms, Experimental
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
Pancreatic carcinoma cells colonizing the liver modulate the expression of their extracellular matrix genes.
|
30603057 |
2018 |
|
Pancreatic Neoplasm
|
0.300 |
Biomarker
|
disease |
CTD_human |
Pancreatic carcinoma cells colonizing the liver modulate the expression of their extracellular matrix genes.
|
30603057 |
2018 |
|
Experimental Hepatoma
|
0.300 |
Biomarker
|
disease |
CTD_human |
Pancreatic carcinoma cells colonizing the liver modulate the expression of their extracellular matrix genes.
|
30603057 |
2018 |
|
Ureteral obstruction
|
0.300 |
Biomarker
|
phenotype |
CTD_human |
The antihelmenthic phosphate niclosamide impedes renal fibrosis by inhibiting homeodomain-interacting protein kinase 2 expression.
|
28318631 |
2017 |
|
Alloxan Diabetes
|
0.300 |
Therapeutic
|
disease |
CTD_human |
Prevention and treatment of diabetes with resveratrol in a non-obese mouse model of type 1 diabetes.
|
21340626 |
2011 |